№ files_lp_3_process_9_09142
File format: docx
Character count: 2196
File size: 15 KB
Scientific research article presenting a dynamic transmission model assessing the contribution of scaled-up public health interventions and behavioural changes to reductions in hepatitis C incidence among people who inject drugs in Scotland between 2008 and 2015.
Authors:
Woodall H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Affiliated Institutions:
University of Bristol; University of California, San Diego; Glasgow Caledonian University; Health Protection Scotland; University of the West of Scotland
Country:
Scotland, United Kingdom
Study Period:
2008–2015
Topic:
Hepatitis C virus transmission among people who inject drugs
Type of Document:
Scientific research article
Data Source:
Needle Exchange Surveillance Initiative (NESI)
Interventions Examined:
Opiate substitution therapy (OST); Needle and syringe programmes (NSP); HCV treatment; Reduction in high-risk behaviour
Methodology:
Dynamic transmission modelling with calibration to national surveillance data
Key Findings:
Estimated 64% reduction in HCV incidence between 2008 and 2015; approximately 900 infections averted by OST/NSP scale-up; additional reductions linked to behavioural changes and treatment
Geographical Focus:
Scotland
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2013
Region / City:
Australia
Topic:
Hepatitis C Virus Screening
Document Type:
Research Study / Surveillance Report
Institution:
The Kirby Institute; Western Australia Department of Health; Queensland Health; Australian Injecting & Illicit Drug Users League; Tasmanian Department of Health and Human Services
Authors:
J. Iversen, J. Bevan, R. Kemp, A. Madden, F. Smith, L. Maher
Target Population:
People Who Inject Drugs (PWID)
Data Source:
Australian Needle and Syringe Program Survey (ANSPS)
Methodology:
Self-reported diagnostic screening, multivariable logistic regression
Key Findings:
Screening uptake, RNA/genotype testing rates, factors associated with testing
Name:
Kelly E. Green, Ph.D.
Profession:
Clinical Psychologist and Academic Faculty
Current Position:
Assistant Professor of Psychology
Institutional Affiliation:
St. Edward’s University, School of Behavioral and Social Sciences
Additional Appointment:
Research Associate and Clinical Consultant, VA Boston Healthcare System
Education:
Ph.D., M.S., and B.A. in Psychology
Doctoral Institution:
Rutgers University
Dissertation Title:
Client-guided Treatment Development for Worried Drinkers of Various Sexual Orientations
Licensure:
Licensed Clinical Psychologist (Rhode Island); Provisionally Licensed Psychologist (Texas)
Certification:
National Register Health Service Psychologist
Academic Appointments Period:
2005–2015
Clinical Specialization:
Substance Use Disorders and PTSD
Teaching Areas:
Chemical Dependency, Counseling, Research Methods, Personality Disorders
Professional Activities:
University Teaching, Clinical Supervision, Invited Trainings, Program Development
Geographic Scope:
Texas, Rhode Island, Massachusetts, Georgia
Associated Institutions:
Harvard Medical School; Boston University School of Medicine; Department of Veterans Affairs
Note:
Year
Subject:
Viral Hepatitis
Document Type:
Health Department Report
Organization:
Kansas Health Department
Target Audience:
Healthcare providers
Year:
2025
Region / City:
United Kingdom
Subject:
Viral Hepatitis Management
Document Type:
Clinical Guideline
Author:
Lucy Garvey, Sanjay Bhagani, Ranjababu Kulasegaram, Michael Butler, Emma Hathorn, Paul Randal, Sarah Smith, Ryan White, Rachel Halford, Alison Grant, Giovanni Villa, Subathira Dakshina, Sema Mandal, Dan Bradshaw
Target Audience:
Healthcare professionals in sexual health and infectious diseases
Period of Validity:
2025
Approval Date:
July 21, 2025
Version:
1.2
Version Date:
July 21, 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Note:
Year
Topic:
Hepatitis B Virus
Document Type:
Agent Summary
Organization / Institution:
U.S. Department of Health and Human Services, CDC, NIH
Target Audience:
Laboratory personnel, researchers
Description:
This document provides a detailed summary of the Hepatitis B virus, its characteristics, risks, transmission, diagnosis, and biosafety precautions for laboratory handling.
Year:
2018
Region / city:
Australia
Topic:
Immunisation, Hepatitis B
Document type:
Report
Agency / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Chief Medical Officer
Target audience:
Healthcare professionals, policymakers
Period of validity:
Until 31 December 2019
Date of approval:
June 2018
Date of amendments:
None
Year:
2003
Region / city:
United States
Topic:
Hepatitis C, Clinical Reports, VISTA System
Document Type:
User Manual
Organization / Institution:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Local Coordinators, Managers, Clinicians
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
This user manual provides instructions for using the CPRS Query Tool for generating Hepatitis C-related clinical reports within the VISTA system.
Year:
2024
Region / city:
Australia
Theme:
Hepatitis B, Vaccination, Disease Surveillance
Document type:
Epidemiological review
Organ / institution:
Australian Government Department of Health
Authors:
Nicole Sonneveld, Joanne Jackson, Aditi Dey, Stephen Lambert, Katrina Clark, Benjamin Cowie, Kristine Macartney, Frank Beard
Target audience:
Researchers, health professionals, policymakers
Period of action:
2000–2019
Approval date:
24/06/2024
Date of changes:
N/A
Year:
2023
Region / city:
Not specified
Topic:
Hepatitis B, Hepatitis C, Public health
Document type:
Data collection form
Organization / institution:
Centers for Disease Control and Prevention (CDC)
Author:
Not specified
Target audience:
Healthcare professionals, Public health departments
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Contextual description:
A form used to gather clinical and diagnostic data from patients with recent hepatitis B or C infections, without known risk factors, to assess potential healthcare exposure windows for further public health investigation.
Year:
2024
Region / City:
UK
Topic:
Hepatitis A, Public Health Surveillance
Document Type:
Questionnaire
Organization:
UKHSA
Authors:
Maya Gobin, Koye Balogun, Obaghe Edeghere
Target Audience:
Public Health Professionals, Healthcare Workers
Effective Period:
2024 - ongoing
Approval Date:
March 2024
Review Date:
April 2024
Version:
1.2
Last Modified:
March 2024
Year:
2023
Region / city:
England
Subject:
Vaccination, Hepatitis A
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Sema Mandal, David Green
Target audience:
Healthcare practitioners
Period of validity:
31 October 2023 - 31 October 2026
Approval date:
5 October 2023
Review date:
31 March 2026
Expiry date:
31 October 2026
Version:
V5.00
Changes history:
Updated with new vaccine licensed for children, changes to vaccine administration routes
Description:
A PGD for the administration of the Hepatitis A vaccine to individuals at high risk, developed and authorised by UKHSA.
Year:
2015
Region / city:
Australia, New Zealand
Topic:
Hepatitis A virus inactivation in berries
Document type:
Guideline
Organization:
Food Standards Australia New Zealand, Ministry for Primary Industries
Author:
FSANZ Risk Assessment (Microbiology), Ministry for Primary Industries
Target audience:
Food manufacturers, food safety professionals
Period of validity:
Not specified
Approval date:
December 2015
Date of changes:
Not specified
Year:
2013
Region / City:
North Central
Topic:
Hepatitis B vaccination
Document Type:
Informed consent form
Organization:
North Central Health Care
Author:
N/A
Target Audience:
Employees at risk of Hepatitis B exposure
Period of validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Journal:
World Journal of Gastroenterology
Manuscript NO:
90838
Manuscript Type:
Letter to the Editor
Authors:
Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo, Stella De Nicola
Affiliations:
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy; Department of Emergency, Humanitas Research Hospital, Milan, Italy
Corresponding Author:
Francesca Colapietro, MD, Department of Biomedical Sciences, Humanitas University, Milan, Italy, [email protected]
Received:
December 15, 2023
Revised:
January 11, 2024
Accepted:
February 18, 2024
Keywords:
Chronic hepatitis B, Reactivation, Nucleoside analogue, Tyrosine kinase inhibitors, Onco-hematology
Study Type:
Case report and literature review
Patient Details:
67-year-old Caucasian male with chronic lymphocytic leukemia, HBsAg-/anti-HBc+
Treatment:
Tyrosine kinase inhibitors, specifically acalabrutinib
Clinical Outcome:
HBV reactivation with liver failure, treated with nucleos(t)ide analogues
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.